Rheonix, Inc. to Present Data on Rheonix CARD® Technology at AACC Annual Meeting

Ithaca, NY – July 19, 2011 – Rheonix, Inc. today announced that data demonstrating the powerful, automated molecular diagnostic capabilities of the Rheonix CARD® system will be presented in a poster session at the American Association for Clinical Chemistry (AACC) Annual Meeting being held in Atlanta, GA, July 24-28, 2011. Rheonix will also exhibit at the Clinical Lab Expo, Booth #4434.

“We now have a robust data set supporting our fully automated diagnosis of bloodstream infection from whole blood using our Rheonix CARD platform in a new application, termed SeptiCARD,” said Tony Eisenhut, President of Rheonix, Inc. “SeptiCARD is able to analyze whole blood for the presence of Septicemia agents within a three-hour period, a speed unmatched in current diagnostic procedures.”

The Rheonix SeptiCARD, still in research phase and not yet FDA cleared for in vitro diagnostic use, utilizes a novel dual-stage nucleic acid purification procedure designed to conduct multiplexed microbial detection for sepsis diagnosis. For the study presented, whole blood was spiked with known amounts of Candida albicans, E. coli and enterococcus and subsequently processed. All steps of cell lysis, dual-stage DNA purification, multiplex PCR and endpoint detection are enclosed and fully contained within the SeptiCARD, allowing for fully-automated detection and reduced risk of cross-contamination.

Rheonix Presentation at AACC:

Wednesday, July 27, 2:00 PM – 4:30 PM Eastern Time

  • Presentation number D-110, “Two-step DNA Isolation Followed by PCR in a Fully Automated System to Detect Septicemia Agents in Whole Blood”